May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Incidence of Endophthalmitis Related to Intravitreal Injection of Bevacizumab and Ranibizumab
Author Affiliations & Notes
  • D. R. Fintak
    Retina, Barnes Retina Institute, St. Louis, Missouri
  • G. Shah
    Retina, Barnes Retina Institute, St. Louis, Missouri
  • K. Blinder
    Retina, Barnes Retina Institute, St. Louis, Missouri
  • C. Regillo
    Retina, Wills Eye Institute, Philadelphia, Pennsylvania
  • J. Pollack
    Retina, Illinois Retina Associates, Chicago, Illinois
  • J. Heier
    Retina, Ophthalmic Consultants of Boston, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  D.R. Fintak, None; G. Shah, None; K. Blinder, None; C. Regillo, None; J. Pollack, None; J. Heier, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 975. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. R. Fintak, G. Shah, K. Blinder, C. Regillo, J. Pollack, J. Heier; Incidence of Endophthalmitis Related to Intravitreal Injection of Bevacizumab and Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):975. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the overall incidence of endophthalmitis associated with office based intravitreal injections of bevacizumab and ranibizumab.

Methods: : This is a retrospective, consecutive, multi-center case series involving four large clinical sites. Included were all patients receiving at least one injection of intravitreal bevacizumab or intravitreal ranibizumab. Follow-up after each injection was at least four weeks.

Results: : A total of 12,585 injections of intravitreal bevacizumab (1.25mg/0.05cc) and 14,320 injections of intravitreal ranibizumab (0.5mg/0.05cc) were given during the study period. Three patients developed an infectious endophthalmitis following administration of intravitreal bevacizumab, and 3 patients following ranibizumab. Rates of endophthalmitis were 0.02% and 0.02% respectively, with an overall rate of 0.02%.

Conclusions: : The rate of endophthalmitis associated with intravitreal bevacizumab and ranibizumab is low, with an incidence of approximately 1 in 4,500 injections.

Keywords: endophthalmitis • vascular endothelial growth factor • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×